Clindamycin phosphate is a chemically synthesized clindamycin derivative that has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin to exert antibacterial activity. It is active against aerobic Gram-positive cocci (such as Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus, and Pneumococcus), anaerobic Gram-negative rods (such as Bacteroides and Fusobacterium), anaerobic Gram-positive non-spore-forming rods (such as Propionibacterium, Eubacterium, and Actinomyces), and anaerobic and microaerophilic Gram-positive rods (such as Peptococcus, microaerophilic Streptococcus, and Peptostreptococcus).

Clindamycin phosphate is a chemically synthesized clindamycin derivative that has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin to exert antibacterial activity. It is active against aerobic Gram-positive cocci (such as Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus, and Pneumococcus), anaerobic Gram-negative rods (such as Bacteroides and Fusobacterium), anaerobic Gram-positive non-spore-forming rods (such as Propionibacterium, Eubacterium, and Actinomyces), and anaerobic and microaerophilic Gram-positive rods (such as Peptococcus, microaerophilic Streptococcus, and Peptostreptococcus).

Clindamycin phosphate is a chemically synthesized clindamycin derivative that has no antibacterial activity in vitro. After entering the body, it is rapidly hydrolyzed into clindamycin to exert antibacterial activity. It has antibacterial activity against aerobic Gram-positive cocci (such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus, and Pneumococcus), anaerobic Gram-negative rods (such as Bacteroides and Fusobacterium), anaerobic Gram-positive non-spore-forming rods (such as Propionibacterium, Eubacterium, and Actinomyces), and anaerobic and microaerophilic Gram-positive rods (such as Peptococcus, microaerophilic Streptococcus, and Peptostreptococcus).

It mainly acts on H2 receptors on parietal cells, competitively inhibiting histamine, inhibiting basal gastric acid secretion, and also inhibiting gastric acid secretion stimulated by food, histamine gastrin, caffeine and insulin. After 300mg injection, 4 to 5 hours later, basal gastric acid secretion can be inhibited by 80%, and 50% of basal gastric acid can be inhibited for 4 to 5 hours.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. The antibacterial activity against anaerobic bacteria is poor. Enoxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.